A shift in how IoT is secured by default

Tern plc

The release of KeyScaler 2025 marks a transformational moment for organisations wrestling with sprawling IoT and OT device estates. Rather than accepting the traditional burden of manual certificate issuance, policy definition and certificate revocation across thousands or even millions of devices, KeyScaler 2025 introduces a fully automated, AI‑driven trust lifecycle.

Manual processes have long been the Achilles’ heel of large‑scale deployments, introducing delays, human error and security gaps. By embedding AI that continuously monitors device behaviour, identity attributes and compliance posture, KeyScaler 2025 is designed to detect anomalies and potential threats in real time, and to trigger remediation automatically.

The platform incorporates a ‘Policy Intelligence Engine’ that enforces zero‑trust principles dynamically, adapts permissions based on contextual threat data and ensures data exchanges remain encrypted and auditable. For industries such as manufacturing, healthcare, energy or logistics, these features offer critical assurances.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search